(E)-N-hydroxy-3-(4-(methylsulfonyl)phenyl)acrylamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N-hydroxy-3-(4-(methylsulfonyl)phenyl)acrylamide
• 英文别名: (E)-3-(4-methylsulfonylphenyl)prop-2-enehydroxamic acid；(E)-N-hydroxy-3-(4-methylsulfonylphenyl)prop-2-enamide
• 化学式: C₁₀H₁₁NO₄S
• 分子量: 241.268
• InChiKey: AWFYCVJWAOVQFE-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-4-(methylsulfonyl)cinnamic acid 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (E)-N-hydroxy-3-(4-(methylsulfonyl)phenyl)acrylamide
  参考文献：
  名称：

  Hydroxamic Acids Block Replication of Hepatitis C Virus

  摘要：

  Intrigued by the role of protein acetylation in hepatitis C virus (HCV) replication, we tested known histone deacetylase (HDAC) inhibitors and a focused library of structurally simple hydroxamic acids for inhibition of a HCV subgenomic replicon. While known HDAC inhibitors with varied inhibitory profiles proved to be either relatively toxic or ineffective, structureactivity relationship (SAR) studies on cinnamic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid gave rise to compounds 22 and 53, which showed potent and selective anti-HCV activity and therefore are promising starting points for further structural optimization and mechanistic studies.

  DOI：

  10.1021/jm501330g

文献信息

• Hydroxamic Acids Block Replication of Hepatitis C Virus
  作者：Teng Ai、Yanli Xu、Li Qiu、Robert J. Geraghty、Liqiang Chen

  DOI：10.1021/jm501330g

  日期：2015.1.22

  Intrigued by the role of protein acetylation in hepatitis C virus (HCV) replication, we tested known histone deacetylase (HDAC) inhibitors and a focused library of structurally simple hydroxamic acids for inhibition of a HCV subgenomic replicon. While known HDAC inhibitors with varied inhibitory profiles proved to be either relatively toxic or ineffective, structureactivity relationship (SAR) studies on cinnamic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid gave rise to compounds 22 and 53, which showed potent and selective anti-HCV activity and therefore are promising starting points for further structural optimization and mechanistic studies.